Literature DB >> 3038725

Relation of the hepatitis B virus carrier state to hepatocellular carcinoma.

H Popper, D A Shafritz, J H Hoofnagle.   

Abstract

The attempt to divide the large group of chronic HBsAg carriers into "healthy" vs. those with chronic hepatitis of various intensities is sometimes difficult. The major problems are overlap in clinical manifestations, hepatic test results and histologic as well as virologic features. Nevertheless, this separation is not only conceptually important, but may also be useful in patient management, particularly because of the risk of transition to cirrhosis and HCC. Although at least 75% of patients with HCC associated with HBV have cirrhosis, the time point at which the cirrhosis developed is not established, particularly since the vast majority of chronic HBsAg carriers fall into the "healthy" category. Important unanswered questions are, therefore: how often do "healthy" carriers develop cirrhosis and/or HCC, including the time relations between the two? Does the transformation to HCC result from one or several identifiable acute events in the "healthy" carrier (or in mild CPH) or is it a gradual process of progressing chronic hepatitis B in which intercurrent exacerbations may still play a role? Do the quantitative observations as to the relation between persistent HBV infections and HCC in the East apply to Western countries? Our hypothesis concerning pathogenesis is based on pathologic, molecular, clinical and epidemiologic observations and concepts, and is supported by studies of hepadna virus-infected animals. This thesis proposes that integration of HBV DNA into host chromosomes in acute or chronic hepatitis or during the "healthy" carrier state corresponds to an initiation event similar to that described in chemical carcinogenesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038725     DOI: 10.1002/hep.1840070425

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

1.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

Authors:  E M Tan
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

2.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

3.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases.

Authors:  R Giacchino; C Navone; F Facco; G Giambartolomei; P Pontisso; F Callea
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

5.  Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.

Authors:  R W King; S K Ladner; T J Miller; K Zaifert; R B Perni; S C Conway; M J Otto
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.

Authors:  B Bressac; K M Galvin; T J Liang; K J Isselbacher; J R Wands; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

7.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

8.  Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma.

Authors:  K H Buetow; J C Murray; J L Israel; W T London; M Smith; M Kew; V Blanquet; C Brechot; A Redeker; S Govindarajah
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.

Authors:  J Petersen; M Dandri; A Bürkle; L Zhang; C E Rogler
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

10.  Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice.

Authors:  P N Gilles; G Fey; F V Chisari
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.